UMECLIDINIUM AND VILANTEROL FORMULATION AND INHALER
A composition comprising particulate umeclidinium or a pharmaceutically acceptable salt or solvate thereof, particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof, and 1,1-difluoroethane.
1 . A composition comprising:
particulate umeclidinium or a pharmaceutically acceptable salt or solvate thereof;
particulate vilanterol trifenatate; and
1,1-difluoroethane (HFA-152a).
2 . The composition of claim 1 , wherein the umeclidinium or a pharmaceutically acceptable salt or solvate thereof is umeclidinium bromide.
3 . The composition of claim 1 , wherein the vilanterol or a pharmaceutically acceptable salt or solvate thereof is vilanterol trifenatate.
4 . The composition of claim 1 , wherein the propellant consists essentially of 1,1-difluoroethane (HFA-152a).
5 . The composition of claim 1 , wherein the canister size of the umeclidinium is between about 2 micrometers and 4 micrometers.
6 . The composition of claim 1 , wherein the canister size of the vilanterol is between about 1 micrometer and 2 micrometers.
7 . The composition of claim 1 , wherein the concentration of the umeclidinium is between about 0.5 mg/g and 5.0 mg/g.
8 . The composition of claim 1 , wherein the concentration of the vilanterol is between about 0.2 mg/g and 2.6 mg/g.
9 . A composition comprising:
particulate umeclidinium or a pharmaceutically acceptable salt or solvate thereof;
particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof; and
1,1-difluoroethane (HFA-152a), wherein umeclidinium and vilanterol or the pharmaceutically acceptable salts or solvates thereof are the only active medicaments in the composition.
10 . The composition of claim 9 , wherein the umeclidinium or a pharmaceutically acceptable salt or solvate thereof is umeclidinium bromide.
11 . The composition of claim 9 , wherein the vilanterol or a pharmaceutically acceptable salt or solvate thereof is vilanterol trifenatate.
12 . The composition of claim 9 , wherein the propellant consists essentially of 1,1-difluoroethane (HFA-152a).
13 . The composition of claim 9 , wherein the canister size of the umeclidinium is between about 2 micrometers and 4 micrometers.
14 . The composition of claim 9 , wherein the canister size of the vilanterol is between about 1 micrometer and 2 micrometers.
15 . The composition of claim 9 , wherein the concentration of the umeclidinium is between about 0.5 mg/g and 5.0 mg/g.
16 . The composition of claim 9 , wherein the concentration of the vilanterol is between about 0.2 mg/g and 2.6 mg/g.
17 . An aerosol canister comprising the composition of claim 1 .
18 . The aerosol canister of claim 17 comprising at least one surface having a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group disposed thereon, wherein the primer composition has a coating composition comprising an at least partially fluorinated compound disposed thereon.
19 . The aerosol canister of claim 18 , wherein the at least partially fluorinated compound is a polyfluoropolyether silane.
20 . (canceled)
21 . An inhaler comprising the aerosol canister of claim 17 .